Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) EBITDA Margin: 2018-2021

  • Genmab A's EBITDA Margin fell 3117.00% to 0.00% in Q2 2021 from the same period last year, while for Jun 2021 it was 0.00%, marking a year-over-year decrease of 992.00%. This contributed to the annual value of 23.59% for FY2020, which is 1689.00% down from last year.
  • Genmab A's EBITDA Margin amounted to 0.00% in Q2 2021, which was down 100.00% from 29.35% recorded in Q4 2020.
  • Genmab A's 5-year EBITDA Margin high stood at 52.12% for Q4 2019, and its period low was -20.46% during Q2 2019.
  • Over the past 3 years, Genmab A's median EBITDA Margin value was 29.35% (recorded in 2020), while the average stood at 18.43%.
  • As far as peak fluctuations go, Genmab A's EBITDA Margin spiked by 5,162bps in 2020, and later plummeted by 3,117bps in 2021.
  • Quarterly analysis of 4 years shows Genmab A's EBITDA Margin stood at 30.11% in 2018, then soared by 2,201bps to 52.12% in 2019, then plummeted by 2,277bps to 29.35% in 2020, then plummeted by 3,117bps to 0.00% in 2021.
  • Its EBITDA Margin was 0.00% in Q2 2021, compared to 29.35% in Q4 2020 and 31.17% in Q2 2020.